keyword
MENU ▼
Read by QxMD icon Read
search

Hepatocellular intervention therapy

keyword
https://www.readbyqxmd.com/read/28214411/non-transplant-therapies-for-patients-with-hepatocellular-carcinoma-and-child-pugh-turcotte-class-b-cirrhosis
#1
REVIEW
Alessandro Granito, Luigi Bolondi
Underlying liver cirrhosis is present in most patients with hepatocellular carcinoma, and liver transplantation is the only treatment strategy to cure both diseases. All other hepatocellular carcinoma treatment strategies have to take into account residual liver function that concurs with the patient's prognosis and might limit their feasibility. In patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B (CPT-B), owing to borderline liver function, any intervention might be offset by liver function deterioration...
February 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28202430/vespro-an-individual-patient-data-prospective-meta-analysis-of-selective-internal-radiation-therapy-versus-sorafenib-for-advanced-locally-advanced-or-recurrent-hepatocellular-carcinoma-of-the-sarah-and-sirvenib-trials
#2
Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce Kh Chow, Valérie Vilgrain
BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) has an overall poor prognosis. Currently there are 2 ongoing prospective randomized controlled trials that are evaluating the efficacy and safety of sorafenib and selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres in patients with advanced HCC. The SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma (SARAH; 459 patients) trial is being performed in Europe and the SIRt VErsus SorafeNIB (SIRveNIB; 360 patients) trial in the Asia Pacific region...
February 15, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28190633/novel-5-arylthio-5h-chromenopyridines-as-a-new-class-of-anti-fibrotic-agents
#3
Renukadevi Patil, Anandita Ghosh, Phoebus Sun Cao, Roger D Sommer, Kyle A Grice, Gulam Waris, Shivaputra Patil
Liver fibrosis is a critical wound healing response to chronic liver injury such as hepatitis C virus (HCV) infection. If persistent, liver fibrosis can lead to cirrhosis and hepatocellular carcinoma (HCC). The development of new therapies for preventing liver fibrosis and its progression to cancer associated with HCV infection remains a critical challenge. Identification of novel anti-fibrotic compounds will provide opportunities for innovative therapeutic intervention of HCV-mediated liver fibrosis. We designed and synthesized a focused set of 5-arylthio-5H-chromenopyridines as a new class of anti-fibrotic agents...
February 1, 2017: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28184942/radiological-biomarkers-for-assessing-response-to-locoregional-therapies-in-hepatocellular-carcinoma-from-morphological-to-functional-imaging-review
#4
Xiao-Dan Ye, Zuguo Yuan, Jian Zhang, Zheng Yuan
Many hepatocellular carcinoma (HCC) patients do not qualify for curative surgical intervention and are instead treated with locoregional therapies (LRTs) including ablative and endovascular therapies. Assessment of imaging response is essential in the management of HCC for determining efficacy of therapy and as a surrogate marker for improved survival. The established morphological image biomarkers for tumor burden measurement continue to be applied, as size measurement can easily be used in clinical practice...
March 2017: Oncology Reports
https://www.readbyqxmd.com/read/28061532/palliative-interventions-for-hepatocellular-carcinoma-patients-analysis-of-the-national-cancer-database
#5
Abdulrahman Y Hammad, Jared R Robbins, Kiran K Turaga, Kathleen K Christians, T Clark Gamblin, Fabian M Johnston
BACKGROUND: Palliative therapies are provided to a subset of hepatocellular carcinoma (HCC) patients with the aim of providing symptomatic relief, better quality of life and improved survival. The present study sought to assess and compare the efficacy of different palliative therapies for HCC. METHODS: The National Cancer Database (NCDB), a retrospective national database that captures approximately 70% of all patients treated for cancer in the US, was queried for patients with HCC who were deemed unresectable from 1998-2011...
November 22, 2016: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/28055301/autophagy-orchestrates-adaptive-responses-to-targeted-therapy-in-endometrial-cancer
#6
Núria Eritja, Bo-Juen Chen, Ruth Rodríguez-Barrueco, Maria Santacana, Sònia Gatius, August Vidal, Maria Dolores Martí, Jordi Ponce, Laura Bergadà, Andree Yeramian, Mario Encinas, Joan Ribera, Jaume Reventós, Jeff Boyd, Alberto Villanueva, Xavier Matias-Guiu, Xavier Dolcet, David Llobet-Navàs
Targeted therapies in endometrial cancer (EC) using kinase inhibitors rarely result in complete tumor remission and are frequently challenged by the appearance of refractory cell clones, eventually resulting in disease relapse. Dissecting adaptive mechanisms is of vital importance to circumvent clinical drug resistance and improve the efficacy of targeted agents in EC. Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma...
January 5, 2017: Autophagy
https://www.readbyqxmd.com/read/28028963/micrornas-in-the-occurrence-and-development-of-primary-hepatocellular-carcinoma
#7
REVIEW
Jie Xu, Ji Li, Tai-Hao Zheng, Lian Bai, Zuo-Jin Liu
Hepatocellular carcinoma is one of the deadliest types of cancer. Despite improvements in treatment over the past few decades, patient survival remains poor and there is an urgent need for development of targeted therapies. MicroRNAs represent a class of small RNAs, frequently deregulated in human malignancies. We are reviewing the role of microRNA in the development of primary hepatocellular carcinoma and its use as a biomarker for early diagnosis and clinical treatment. First, we describe the current incidence and possible causes of the incidence of hepatocellular carcinoma, followed by the introduction of microRNA synthesis, maturation and function, and finally we explain the role of microRNA in the development of hepatocellular carcinoma and its clinical value as a biological marker in the diagnosis and treatment of liver cancer...
September 2016: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/28008570/the-role-of-interventional-radiology-in-the-treatment-of-intrahepatic-cholangiocarcinoma
#8
Anna Maria Ierardi, Salvatore Alessio Angileri, Francesca Patella, Silvia Panella, Natalie Lucchina, Elena N Petre, Antonio Pinto, Giuseppe Franceschelli, Gianpaolo Carrafiello, Gianpaolo Cornalba, Constantinos T Sofocleous
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatic malignancy after hepatocellular carcinoma. Complete surgical resection remains the only potentially curative option for patients with ICC. However, until now, early diagnosis with potential surgical intervention has been the exception rather than the rule with only 30% of patients qualifying for attempted surgical cure. Many patients are unresectable because of disease stage, anatomic conditions, medical comorbidities, and small future remnant liver...
January 2017: Medical Oncology
https://www.readbyqxmd.com/read/27995086/hepatocellular-carcinoma-the-role-of-interventional-oncology
#9
REVIEW
Matteo Donadon, Luigi Solbiati, Laura Dawson, Aisling Barry, Gonzalo Sapisochin, Paul D Greig, Shuichiro Shiina, Andrea Fontana, Guido Torzilli
BACKGROUND: Hepatocellular carcinoma (HCC) remains a major health issue because of its increasing incidence and because of the complexity of its management. In addition to the traditional potentially curative treatments, i.e., liver transplantation and surgical resection, other new and emerging local therapies have been applied with promising results. SUMMARY: Radiotherapy (RT) and interstitial treatments, such as radiofrequency ablation (RFA), microwave ablation (MWA), and irreversible electroporation (IRE), have recently opened new and interesting treatment scenarios for HCC and are associated with promising results in selected patients...
November 2016: Liver Cancer
https://www.readbyqxmd.com/read/27995085/transarterial-therapies-for-hepatocellular-carcinoma
#10
REVIEW
Ezio Lanza, Matteo Donadon, Dario Poretti, Vittorio Pedicini, Marco Tramarin, Massimo Roncalli, Hyungjin Rhee, Young Nyun Park, Guido Torzilli
BACKGROUND: The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs. SUMMARY: The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results...
November 2016: Liver Cancer
https://www.readbyqxmd.com/read/27981445/patterns-of-sorafenib-and-tace-treatment-of-unresectable-hepatocellular-carcinoma-in-a-chinese-population-subgroup-analysis-of-the-gideon-study
#11
Fengyong Liu, Zhiqiang Meng, Guoliang Shao, Jianhua Wang, Zhijun Wang, Jijin Yang, Christina S M Yip, Dongfeng He
To analyze safety and efficacy of patterns of sorafenib and TACE therapy under real-life clinical practice conditions. A total of 338 Chinese patients with unresectable hepatocellular carcinoma (HCC) from the international database of the GIDEON non-interventional trial were included in this analysis. Endpoints were overall survival (OS), progression-free survival (PFS), time to progression (TTP) and safety. Two major patterns in the use of sorafenib observed in current Chinese clinical practice were: sorafenib administration subsequent to transarterial chemoembolization (TACE) treatment (n = 226, 66...
December 15, 2016: Molecular Biology Reports
https://www.readbyqxmd.com/read/27930585/the-incidence-and-outcome-of-major-complication-following-conventional-tae-tace-for-hepatocellular-carcinoma
#12
COMPARATIVE STUDY
Jianfei Tu, Zhongzhi Jia, Xihui Ying, Dengke Zhang, Shaoqin Li, Feng Tian, Guomin Jiang
To investigate the incidence and outcome of major complication following conventional transarterial embolization/chemoembolization (TAE/TACE) therapy for hepatocellular carcinoma (HCC).From May 2010 to May 2016, all patients with major complication following conventional TAE/TACE for HCC were included. Major complication was defined as admission to a hospital for therapy, an unplanned increase in the level of care, prolonged hospitalization, permanent adverse sequelae, or death after conventional TAE/TACE therapy by Society of Interventional Radiology...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27908546/effects-of-branched-chain-amino-acid-supplementation-after-radiofrequency-ablation-for-hepatocellular-carcinoma-a-randomized-trial
#13
Shunsuke Nojiri, Kei Fujiwara, Noboru Shinkai, Etsuko Iio, Takashi Joh
OBJECTIVE: Maintenance of liver function is important for better outcomes after radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). The aim of this study was to examine the effects of oral branched-chain amino acid (BCAA) supplementation on liver function, intrahepatic recurrence rate, and incidence of complications after RFA for HCC. METHODS: Patients with cirrhosis who underwent RFA were enrolled between August 2009 and April 2012, randomized to oral supplementation with Aminoleban EN (BCAA group) or diet alone (control group), and followed to determine changes in serum parameters and health status...
January 2017: Nutrition
https://www.readbyqxmd.com/read/27890896/interventional-treatment-of-severe-portal-vein-thrombosis-after-living-donor-liver-transplantation
#14
Youichi Kawano, Satoru Murata, Nobuhiko Taniai, Masato Yoshioka, Atsushi Hirakata, Yoshiaki Mizuguchi, Tetsuya Shimizu, Tomohiro Kanda, Junji Ueda, Hideyuki Takada, Hiroshi Yoshida, Koho Akimaru, Shiro Onozawa, Shinichirou Kumita, Eiji Uchida
Portal vein thrombosis (PVT) is a rare complication of liver transplantation which can lead to graft failure and patient death. Treatment can be difficult, especially in cases of PVT from the intrahepatic portal vein to the proximal jejunal veins. A 55-year-old woman had undergone living-donor liver transplantation with splenectomy for end-stage liver cirrhosis due to hepatitis C with hepatocellular carcinoma. Ten months after transplantation, massive ascites and slight abdominal pain developed, and computed tomography revealed a PVT between the intrahepatic portal vein and the superior mesenteric vein...
2016: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/27870678/interventional-oncology-in-hepatocellular-carcinoma-progress-through-innovation
#15
Lin Mu, Julius Chapiro, Jeremiah Stringam, Jean-François Geschwind
The clinical management of hepatocellular carcinoma has evolved greatly in the last decade mostly through recent technical innovations. In particular, the application of cutting-edge image guidance has led to minimally invasive solutions for complex clinical problems and rapid advances in the field of interventional oncology. Many image-guided therapies, such as transarterial chemoembolization and radiofrequency ablation, have meanwhile been fully integrated into interdisciplinary clinical practice, whereas others are currently being investigated...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27843598/cancer-and-liver-cirrhosis-implications-on-prognosis-and-management
#16
REVIEW
Matthias Pinter, Michael Trauner, Markus Peck-Radosavljevic, Wolfgang Sieghart
Liver cirrhosis, the end-stage of every chronic liver disease, is not only the major risk factor for the development of hepatocellular carcinoma but also a limiting factor for anticancer therapy of liver and non-hepatic malignancies. Liver cirrhosis may limit surgical and interventional approaches to cancer treatment, influence pharmacokinetics of anticancer drugs, increase side effects of chemotherapy, render patients susceptible for hepatotoxicity, and ultimately result in a competitive risk for morbidity and mortality...
2016: ESMO Open
https://www.readbyqxmd.com/read/27816492/tremelimumab-in-combination-with-ablation-in-patients-with-advanced-hepatocellular-carcinoma
#17
Austin G Duffy, Susanna V Ulahannan, Oxana Makorova-Rusher, Osama Rahma, Heiner Wedemeyer, Drew Pratt, Jeremy L Davis, Marybeth S Hughes, Theo Heller, Mei ElGindi, Ashish Uppala, Firouzeh Korangy, David E Kleiner, William D Figg, David Venzon, Seth M Steinberg, Aradhana M Venkatesan, Venkatesh Krishnasamy, Nadine Abi-Jaoudeh, Elliot Levy, Brad J Wood, Tim F Greten
BACKGROUND & AIMS: Tremelimumab is a fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of activated T lymphocytes. Ablative therapies induce a peripheral immune response which may enhance the effect of anti-CTLA4 treatment in patients with advanced hepatocellular carcinoma (HCC). This study aimed to demonstrate whether tremelimumab could be combined safely and feasibly with ablation. METHODS: Thirty-two patients with HCC were enrolled: male:female: 28:4; median age: 62 (range 36-76)...
March 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/27784441/-studies-on-telomerase-reverse-transcriptase-components-and-liver-cancer
#18
REVIEW
J J Cai, X L Guo
Telomeres are DNA tandem repeats at the ends of chromosomes in eukaryotic cells and play important roles in maintaining the stability and integrity of chromosomes. Telomeres are gradually shortened with cell proliferation, and when they are shortened to a certain length, the cells experience senescence and apoptosis. However, a small number of cells can maintain the length of telomeres and restore their function through related mechanisms (activation of telomerase or other mechanisms), and some cells may even be immortalized...
July 20, 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/27776657/vegfr-2-expression-in-hcc-dysplastic-and-regenerative-liver-nodules-and-correlation-with-pre-biopsy-dynamic-contrast-enhanced-ct
#19
W M Thaiss, S Kaufmann, C Kloth, K Nikolaou, H Bösmüller, M Horger
PURPOSE: To evaluate whether VEGFR-2-expression in hepatocellular carcinoma (HCC), dysplastic (DLN) and regenerative liver nodules (RLN) correlates with pre-histology, in vivo Dynamic Contrast Enhanced-Computed Tomography (DCE-CT) data as VEGFR-2-expression affects prognosis and therapeutic options. MATERIALS AND METHODS: 34 patients (63.6±8.9years, 7 females) underwent liver biopsy or surgery due to suspected HCC or dysplastic nodules after DCE-CT between 2009 and 2015 with no previous chemo- or interventional therapy...
November 2016: European Journal of Radiology
https://www.readbyqxmd.com/read/27771453/field-battle-against-hepatitis-b-infection-and-hcc-in-africa
#20
REVIEW
Maud Lemoine, Mark R Thursz
Despite effective and safe HBV vaccine and antiviral therapies, HBV-related hepatocellular carcinoma remains a major cause of deaths in young adults in Africa. Barriers to control the burden of HBV infection and HCC are multiple. In comparison to other major infectious diseases, hepatitis B virus infection and liver diseases have received remarkably little attention from the global health community. Improving birth dose vaccine coverage and implementing screening and treatment interventions are urgently needed...
October 19, 2016: Journal of Hepatology
keyword
keyword
84489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"